<DOC>
	<DOCNO>NCT03014102</DOCNO>
	<brief_summary>The purpose study determine whether recombinant human thrombopoietin effective peripheral blood progenitor cell mobilization autologous transplantation .</brief_summary>
	<brief_title>Recombinant Human Thrombopoietin Mobilization Peripheral Blood Progenitor Cells Autologous Transplantation</brief_title>
	<detailed_description />
	<criteria>histologically confirm diagnosis Hodgkin 's disease , nonHodgkin 's lymphoma , select highrisk solid tumor plan receive autologous peripheral blood progenitor cell transplantation Eastern Cooperative Oncology Group performance status 0 2. abnormal liver function ( aminotransferase bilirubin level 2 time upper limit normal ) , leukopenia ( white blood cell count 3000/L ) , history platelet disorder associate bleed diathesis history thromboembolic disease , coronary heart disease , stroke , arrhythmia , central nervous system metastasis , organ system diseases abnormality might predispose individual treatmentrelated complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>